ライフサイエンスコーパス: kidney failure

1 ing for death may overestimate their risk of kidney failure.

2 cted to preventing the progression of CKD to kidney failure.

3 cular hemolysis, thrombocytopenia, and acute kidney failure.

4 lar filtration, and leads to proteinuria and kidney failure.

5 tinine level, acute kidney injury (AKI), and kidney failure.

6 veloped incorporating ACR to predict risk of kidney failure.

7 n, including a small increase in the risk of kidney failure.

8 become the preferred treatment for end stage kidney failure.

9 form of primary GN and an important cause of kidney failure.

10 regnant adults aged >/=20 y who did not have kidney failure.

11 timately leads to loss of renal function and kidney failure.

12 ey disease, an important and common cause of kidney failure.

13 d glomerular disease is the leading cause of kidney failure.

14 , yet aged animals display no overt signs of kidney failure.

15 glomerular aneurysm and perinatal death from kidney failure.

16 of the glomerulus and is a leading cause of kidney failure.

17 yielding kidney injury and in some patients, kidney failure.

18 oxalate by lactate dehydrogenase, leading to kidney failure.

19 phropathy to patients at the highest risk of kidney failure.

20 emolytic anemia, thrombocytopenia, and acute kidney failure.

21 initiation of autophagy, cell apoptosis, and kidney failure.

22 hereditary glomerular disease that leads to kidney failure.

23 is, nephrotic-range proteinuria, and finally kidney failure.

24 iscoidal LDLs and HDL particles, and develop kidney failure.

25 re proteinuria, foot process effacement, and kidney failure.

26 atients with both endstage liver disease and kidney failure.

27 xtended the life expectancy of patients with kidney failure.

28 ne, a hallmark of cardiovascular disease and kidney failure.

29 dult mice resulted in severe proteinuria and kidney failure.

30 tract are the most common cause of pediatric kidney failure.

31 in progressive kidney damage and ultimately kidney failure.

32 0.03); 1 patient in each group had end-stage kidney failure.

33 tor for coronary artery disease, stroke, and kidney failure.

34 attack, stroke and progression to heart and kidney failure.

35 ften associated with pain, hypertension, and kidney failure.

36 nsion, eventually culminating in progressive kidney failure.

37 dulin deficiency precedes but does not cause kidney failure.

38 ically important outcomes, such as death and kidney failure.

39 ns do not form and newborn mice die owing to kidney failure.

40 uremic syndrome may develop that can lead to kidney failure.

41 phropathy (MN) is a rare autoimmune cause of kidney failure.

42 ed by renal cystic growth and progression to kidney failure.

43 corneal opacities, anemia, proteinuria, and kidney failure.

44 o our understanding and study of preterminal kidney failure.

45 s one of the most common causes of pediatric kidney failure.

46 y of bariatric surgery (BS) in patients with kidney failure.

47 long-term dialysis treatment as a result of kidney failure.

48 l for progression of diabetic nephropathy to kidney failure.

49 idney disease (ESKD) is defined as permanent kidney failure.

50 glomerulonephritis progressing to end-stage kidney failure.

51 nd died several weeks later, presumably from kidney failure.

52 osclerosis, tubulointerstitial fibrosis, and kidney failure.

53 include a poorly characterized risk of late kidney failure.

54 (AA) kidney donors were at greater risk for kidney failure.

55 123) died of CVD, and 66% (n = 548) reached kidney failure.

56 ntify a locus for this common cause of human kidney failure.

57 gregate with hereditary forms of progressive kidney failure.

58 tant role in the pathophysiology of ischemic kidney failure.

59 conditions such as hypertension and chronic kidney failure.

60 s that underlie the many different causes of kidney failure.

61 tion, renal proximal tubule dysfunction, and kidney failure.

62 isodes of ureteral obstruction with eventual kidney failure.

63 arly death of affected children often due to kidney failure.

64 ney stones, nephrocalcinosis, and ultimately kidney failure.

65 PH patients and not applicable in those with kidney failure.

66 group of rare genetic diseases that lead to kidney failure.

67 njury and the risk of disease progression to kidney failure.

68 timate the population most at-risk for later kidney failure.

69 and organ damage, and ultimately progressive kidney failure.

70 nephropathy is a leading cause of end-stage kidney failure.

71 ed in the risk of heart disease, cancer, and kidney failure.

72 ressive kidney disease, leading to end-stage kidney failure.

73 ar capillaries, thereby promoting injury and kidney failure.

74 and ethical frameworks for the treatment of kidney failure.

75 glomerulosclerosis (FSGS), a common cause of kidney failure.

76 sease (CKD), while 3 in 100 will progress to kidney failure.

77 tract (CAKUT) are a major cause of pediatric kidney failure.

78 for zero or one versus two copies of GSTM1: kidney failure, 1.66 [1.27 to 2.17]; heart failure, 1.16

79 ion cohorts included 3449 patients (386 with kidney failure [11%]) and 4942 patients (1177 with kidne

80 Risk factors for subsequent kidney failure (13% at 5 years posttransplant) were seru

81 failure [11%]) and 4942 patients (1177 with kidney failure [24%]), respectively.

82 t ureter ligation, causes irreversible right kidney failure 3, 6 or 9 months after AKI.

83 y significant difference in the incidence of kidney failure (31.7% with intervention vs 27.3% with pl

84 Eight studies (11 models) involved kidney failure, 5 studies (6 models) involved all-cause

85 e, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in

86 Diabetes is the leading cause of kidney failure, accounting for >45% of new cases of dial

87 a 22-year-old patient who developed chronic kidney failure after receiving haploidentical HSCT from

88 of PI3Kbeta sensitizes mice to lethal acute kidney failure after TMA injury.

89 pathy (IgAN) represents the leading cause of kidney failure among East Asian populations and the most

90 rome (HUS) is the most common cause of acute kidney failure among US children.

91 e proportion of patients who never developed kidney failure and (2) median number of days alive and f

92 e 0.68 (95% CI, 0.57 to 0.82; P < 0.001) for kidney failure and 0.77 (CI, 0.65 to 0.91; P = 0.0024) f

93 Key secondary outcomes included kidney failure and 30-day mortality.

94 s at risk; mean age 77 years), 18% developed kidney failure and 53% died.

95 ephron damage and renal fibrosis, leading to kidney failure and a premature death rate of 67% by 9 we

96 otein associated with a higher risk for both kidney failure and all-cause mortality.

97 thy) lead to increased mortality, blindness, kidney failure and an overall decreased quality of life

98 e 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in th

99 l fibrosis surrounding collecting ducts with kidney failure and death by 3-4 weeks of age.

100 In CKD, the risk of kidney failure and death depends on the severity of prot

101 ciated with an increased risk for subsequent kidney failure and death.

102 sts underlying PVN with an increased risk of kidney failure and dialysis.

103 he FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidne

104 ent of proteinuria, resulting in progressive kidney failure and focal segmental glomerulosclerosis.

105 skin disorder that develops in patients with kidney failure and has been linked to exposure to gadoli

106 a new mechanism of pathologic thrombosis and kidney failure and have immediate implications for treat

107 copy of GSTM1 associated with higher risk of kidney failure and heart failure (adjusted hazard ratio

108 ss of GSTM1 is also associated with incident kidney failure and heart failure, we estimated GSTM1 cop

109 pain and haemodynamic instability with acute kidney failure and high mortality rate (20%).

110 ours after CC injection completely prevented kidney failure and infarcts.

111 cipients.The incidence of dialysis-dependent kidney failure and infection in the liver transplant pat

112 d their physicians that their early onset of kidney failure and longer period of transplantation and

113 increasingly recognized among patients with kidney failure and may be driven by left heart failure,

114 ointerstitial nephritis is a common cause of kidney failure and may have diverse etiologies.

115 scular events, graft loss and progression of kidney failure and mortality in renal transplant recipie

116 25)I iothalamate GFR, expressed per SD, with kidney failure and mortality.

117 concerns about future increased incidence of kidney failure and other complications of CKD.

118 icated Stx2 as the sole contributor to acute kidney failure and other systemic complications in human

119 Progression to kidney failure and recurrence with graft loss after kidn

120 downward spiral of injury toward progressive kidney failure and should, therefore, be investigated.

121 period, 102 previous kidney donors developed kidney failure and were listed for kidney transplantatio

122 sociated with neurological abnormalities and kidney failure and, as an acid glucocerebrosidase recept

123 urred in 5715 participants without prevalent kidney failure, and 1028 heart failure events occurred i

124 564 of the 3,478 participants progressed to kidney failure, and 803 died.

125 ction, associated with a significant risk of kidney failure, and an abnormal facial expression upon s

126 racterised by retinal degeneration, obesity, kidney failure, and cognitive impairment.

127 hythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation,

128 uch as infection, gastrointestinal bleeding, kidney failure, and liver fibrosis.

129 re autoimmune crescentic glomerulonephritis, kidney failure, and lung hemorrhage due to binding of pa

130 procedure in the treatment of patients with kidney failure, and requires collaboration of experts fr

131 ir in models of myocardial infarction, acute kidney failure, and stroke through the action of trophic

132 renal donation because of their own risk of kidney failure; and consideration of genetic testing to

133 obesity, chronic heart failure, and chronic kidney failure are characterized by the accumulation of

134 In Alberta, Canada, rates of untreated kidney failure are significantly higher in older compare

135 Cy/+ rats with PKD have kidney failure as indicated by a significant increase in

136 by ferrocene for Cystatin C (CysC), an early kidney failure biomarker, is described.

137 creatinine associated with a higher risk for kidney failure but a lower risk for all-cause mortality.

138 tein, each remained directly associated with kidney failure but differed with respect to their associ

139 losclerosis commonly progresses to end-stage kidney failure, but pathogenic mechanisms are still poor

140 GFR decline leads to kidney failure, but regulators have not approved using d

141 Renal ciliopathies are a leading cause of kidney failure, but their exact etiology is poorly under

142 prevent or delay serious sequelae, including kidney failure, cardiovascular disease, and premature de

143 dney disease (CKD) are at increased risk for kidney failure, cardiovascular events, and all-cause mor

144 ast 1-year follow-up; and outcomes of death, kidney failure, cardiovascular events, change in kidney

145 orted on a model that predicted the risk for kidney failure, cardiovascular events, or all-cause mort

146 eople, and is an independent risk factor for kidney failure, cardiovascular morbidity and death.

147 risk factor for the progression to end-stage kidney failure, cardiovascular morbidity, and premature

148 cribe these challenges - equity in access to kidney failure care, avoiding futile dialysis, reducing

149 ng dialysis costs, shared decision-making in kidney failure care, living donor risk evaluation and de

150 n monogenetic disorders, is characterized by kidney failure caused by bilateral renal cyst growth.

151 e; 78% were white; 63% were men; and 20% had kidney failure caused by diabetes mellitus.

152 Ia) are reported in four of 17 children with kidney failure caused by renal adysplasia in the absence

153 wheat flour causes a dose-dependent chronic kidney failure characterized by renal tubulointerstitial

154 ulation of homocysteine (Hcy) during chronic kidney failure (CKD) can exert toxic effects on the glom

155 adverse outcomes (death, dialysis-dependent kidney failure (DDKF), and cardiovascular outcomes) for

156 ada, we analyzed the time to the earliest of kidney failure, death, or censoring, using methods that

157 te increased significantly as their risk for kidney failure decreased, as the payment offered increas

158 After the randomized trial was completed, kidney failure (defined as initiation of dialysis or kid

159 Participants were followed up for kidney failure (defined as the initiation of dialysis or

160 Kidney failure, defined as need for dialysis or preempti

161 Patients with chronic kidney failure--defined as a glomerular filtration rate

162 utcome measure was either death or end-stage kidney failure (dependence on dialysis) at 90 days after

163 ion, but many patients progress to end-stage kidney failure despite optimal therapy.

164 , all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocyst

165 findings reaffirm that disease pathways for kidney failure differ by donor phenotype and estimate th

166 inflammation is associated with progressive kidney failure due to activation of the NLRP3/CASP-1 inf

167 We defined three patterns of artificial kidney failure: early (<= 12 hr), intermediate (> 12-24

168 ollow-up time of 74.0 months, there were 327 kidney failure events and 202 deaths.

169 iferous vegetables was associated with fewer kidney failure events compared with low consumption, but

170 Over a median follow-up of 24.6 years, 256 kidney failure events occurred in 5715 participants with

171 Eight patients with end-stage kidney failure (five men, three women, mean age 51.7 [SD

172 (2) median number of days alive and free of kidney failure for patients who did not survive, who exp

173 three individuals who have been affected by kidney failure for their views on the importance of unde

174 rulonephritis is an important cause of human kidney failure for which the underlying molecular basis

175 HICs, and globally, most people who develop kidney failure forego treatment, resulting in millions o

176 The primary outcome was kidney failure-free days during the 28-day period after

177 The median number of kidney failure-free days for patients who did not surviv

178 norepinephrine did not improve the number of kidney failure-free days.

179 Except for 1 acute kidney failure, grade 3, due to tumor lysis syndrome, ov

180 gadolinium contrast agents in patients with kidney failure has markedly decreased, patients with exp

181 to kidney transplantation for patients with kidney failure have been well described.

182 Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and amputation of

183 icantly increased the rate of progression to kidney failure in a Col4a3(-/-) mouse model of autosomal

184 bstructive nephropathy, the leading cause of kidney failure in children, can be anatomic or functiona

185 olytic uremic syndrome, the leading cause of kidney failure in children, often follows infection with

186 a relative risk reduction for progression to kidney failure in CKD >= stage 3 patients of 70% at 2 ye

187 hypertension, mitochondrial dysfunction, and kidney failure in Col4a3(-/-) mice, a model of human Alp

188 hy (HIVAN), the most common cause of chronic kidney failure in HIV-infected patients.

189 he most common genetic disease that leads to kidney failure in humans.

190 ed increased prevalence of IgAN-attributable kidney failure in Northern Europe.

191 Studies of kidney failure in older adults have focused on receipt o

192 ric surgery alters the progression of CKD to kidney failure in patients who are severely obese.

193 ensin-converting enzyme slows progression to kidney failure in patients with Alport syndrome but is n

194 lly validated models for predicting risk for kidney failure in patients with CKD are available and re

195 tests can accurately predict progression to kidney failure in patients with CKD stages 3 to 5.

196 antation plays an important role in treating kidney failure in patients with end-stage liver disease.

197 itial Jak/Stat expression and progression of kidney failure in patients with type 2 diabetic nephropa

198 ve fibrosis are common pathways that lead to kidney failure in proteinuric nephropathies.

199 CLF with kidney failure than in ACLF without kidney failure in the absence of differences in urine KP

200 higher rates of both hyperkalemia and acute kidney failure in the early (1.3% and 2.7%, respectively

201 nsights into the pathogenesis of progressive kidney failure in the setting of lymphoproliferative dis

202 disease (DKD) is the single leading cause of kidney failure in the U.S., for which a cure has not yet

203 BK polyomavirus (PyV) is a major source of kidney failure in transplant recipients.

204 chemical studies confirmed and characterized kidney failure in xor-nullizygous mice.

205 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of

206 d mortality, and both heart failure (HF) and kidney failure incidences are increasing.

207 disease initiation prevented albuminuria and kidney failure, indicating miR-92a inhibition as a poten

208 Kidney failure influences the treatment outcomes of abdo

209 Progressive kidney failure is a genetically and clinically heterogen

210 An inherited, late-onset form of kidney failure is caused by point mutations in the alpha

211 nformation regarding risk for progression to kidney failure is required for clinical decisions about

212 ns, which usually results in proteinuria and kidney failure, is caused by mutations to the COL4A3, CO

213 D), the most common genetic cause of chronic kidney failure, is characterized by the presence of nume

214 renal replacement treatment modalities, and kidney failure itself.

215 ected at an early stage but can cause lethal kidney failure later on.

216 derate (>/=30-< 60), severe (>/=15-<30), and kidney failure (<15 or dialysis).

217 a provide indirect evidence that the risk of kidney failure may be exaggerated in AA donors.

218 1.04 [0.86 to 1.26]), or dialysis-dependent kidney failure (n=343 events; 1.15 [0.93 to 1.43]) compa

219 e dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.

220 Kidney failure occurred in 554 participants (66%), and t

221 In severe cases, kidney failure occurs during adolescence or early adulth

222 E (risk for renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney funct

223 c kidney disease (CKD), in whom the cause of kidney failure often remains unknown.

224 of cardiovascular mortality in patients with kidney failure on dialysis.

225 he KRd group (four cardiotoxicity, two acute kidney failure, one liver toxicity, two respiratory fail

226 transplantation) and a composite outcome of kidney failure or all-cause mortality were ascertained t

227 predictors of risk and the composite outcome kidney failure or creatinine doubling, was developed and

228 of an MG is associated with a higher risk of kidney failure or death in individuals with chronic kidn

229 The 24-hr urinary samples of patients with kidney failure or on renal replacement therapy were excl

230 xcluded from the primary analysis because of kidney failure or patient death.

231 sociated with a significantly higher risk of kidney failure or, unlike in the general population, ris

232 atients who did not survive, who experienced kidney failure, or both was 9 days (interquartile range

233 atients who did not survive, who experienced kidney failure, or both.

234 stimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD

235 take of F(-) can result in dental fluorosis, kidney failure, or DNA damage.

236 d-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therap

237 or phrases "nephrotoxicity," "nephropathy," kidney failure," or "renal failure." The identified publ

238 iovascular disease (CVD), heart failure, and kidney failure outcomes.

239 death increasingly overestimated the risk of kidney failure over time from 7% at 5 years to 19% at 10

240 Rates of kidney failure overall (treated and untreated combined)

241 th normal eGFR, but not in those with CKD or kidney failure (P for interaction=0.05).

242 ucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or tr

243 Moreover, in patients with kidney failure, peritoneal dialysis significantly decrea

244 velop a recessive phenotype characterized by kidney failure, proteinuria, glomerulosclerosis, and ret

245 of these advances has the potential to delay kidney failure, reduce the symptom burden, lessen the ri

246 ric reflux accounts for approximately 10% of kidney failure requiring dialysis or transplantation, an

247 CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy.

248 d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).

249 eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively.

250 moderate impairment, severe impairment, and kidney failure, respectively.

251 Most kidney failure risk calculators are based on methods tha

252 Kidney failure risk calculators should account for death

253 The Kidney Failure Risk Equation (KFRE) uses the 4 variables

254 FR<60 ml/min per 1.73 m(2), we then used the kidney failure risk equation to compare kidney failure r

255 the kidney failure risk equation to compare kidney failure risk using measured ACR as well as estima

256 Estimates of kidney failure risk were similar using measured ACR and

257 ntravital microscopy of animals with chronic kidney failure showed that FGF23 inhibits chemokine-acti

258 7.4 %, of life-threatening bleeding 7.4%, of kidney failure stage III 7.4%, and of major access site

259 addition, the heterogeneity of patients with kidney failure suggests it is unlikely that a 'one-size-

260 cause participants were more likely to reach kidney failure than death in follow-up.

261 th SI; it was remarkably higher in ACLF with kidney failure than in ACLF without kidney failure in th

262 97,451 (5.36%) died, 3295 (0.18%) developed kidney failure that was treated and 3116 (0.17%) develop

263 that was treated and 3116 (0.17%) developed kidney failure that went untreated.

264 the impact of the SNPs on dialysis-dependent kidney failure, the incidence of infections and patient

265 For kidney failure, the increased risks were 2.81 (CI, 2.48

266 rticipants' risk for subsequently developing kidney failure themselves, and who would receive the don

267 The prevalence and incidence of kidney failure treated by dialysis and transplantation i

268 LC-MG was not associated with risk of kidney failure (univariable SHR 1.07 [95% CI 0.58 to 1.9

269 esence of MG was not associated with risk of kidney failure (univariable subhazard ratio [SHR] 0.97 [

270 rtality, cardiovascular (CVD) mortality, and kidney failure until December 2000.

271 -induced cytokine release, inflammation, and kidney failure using in vitro and in vivo models.

272 d risk of the combined end point of death or kidney failure was 64% at 5 years and 87% at 10 years.

273 Mean access pressure in late artificial kidney failure was 7.5 mm Hg (7.1-7.9 mm Hg) less negati

274 The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%) in the vas

275 The risk of progression from CKD to kidney failure was assessed using the Chronic Kidney Dis

276 Within each eGFR stratum the rate of treated kidney failure was higher in younger compared with older

277 athogenesis provoking glomerulonephritis and kidney failure was nonhematopoietic in origin, independe

278 isk reduction in the progression from CKD to kidney failure was observed.

279 process effacement leads to proteinuria and kidney failure, we studied the function of FAK in podocy

280 Rates of untreated kidney failure were consistently higher at older ages.

281 Associations with the risk of kidney failure were estimated by competing-risks regress

282 9 mL/min/1.73 m2), adjusted rates of treated kidney failure were more than 10-fold higher among the y

283 mL/min/1.73 m2, adjusted rates of untreated kidney failure were more than 5-fold higher among the ol

284 rosis is responsible for chronic progressive kidney failure, which is present in a large number of ad

285 n heavy albuminuria, glomerulosclerosis, and kidney failure, which led to animal death beginning at 1

286 Performance in patients with terminal kidney failure who are receiving long-term dialysis cann

287 ge volumes of fluid removal in patients with kidney failure who are treated with intermittent haemodi

288 technique failure in patients with end stage kidney failure who receive peritoneal dialysis (PD).

289 Experimental studies in patients with kidney failure who were treated with intermittent haemod

290 t mice developed progressive proteinuria and kidney failure with global or segmental glomeruloscleros

291 this is related directly to the treatment of kidney failure with HD or to the higher prevalence of ob

292 life-threatening problem in the treatment of kidney failure with peritoneal dialysis.

293 been identified as the cause for progressive kidney failure with urinary protein loss.

294 st formation, kidney enlargement, and severe kidney failure, with a mean survival time of 2 months.

295 with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative str

296 nockout (KO) mice, which develop spontaneous kidney failure, with that of Col4a3;Tsp1 double-knockout

297 Mice homozygous for the mutation died from kidney failure within 72 hours after birth.

298 kidney disease (DKD) is the leading cause of kidney failure worldwide and the single strongest predic

299 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term tr

300 n study of IgA nephropathy, a major cause of kidney failure worldwide.